Osteoporosis and schizophrenia: Can we limit known risk factors?

Abraham, George; Friedman, Ronald H.; Verghese, Cherian; de Leon, Jose

doi:10.1016/0006-3223(95)00062-l

Cited by 40Schizophrenia research and treatmentBone health and osteoporosis researchBone Metabolism and Diseases

Osteoporosis and schizophrenia: Can we limit known risk factors?

Abraham, George, Friedman, Ronald H., Verghese, Cherian, de Leon, Jose·1995·Biological Psychiatry

DOI 10.1016/0006-3223(95)00062-l

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/0006-3223(95)00062-l

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In comparison with the general population, untreated patients with schizophrenia appear to have an increased risk of developing osteoporosis.
“In comparison with the general population, untreated patients with schizophrenia appear to have an increased risk of developing osteoporosis.”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [473]
The increased risk of osteoporosis in untreated schizophrenia is due to the disease itself and to risk factors related to lifestyle (e.g., smoking, reduced physical activity, alcohol abuse, vitamin D and calcium deficiency, polydipsia).
“On the one hand, this is because of the disease itself, on the other hand, because of risk factors related to their lifestyle (e.g., smoking, reduced physical activity, alcohol abuse, vitamin D and calcium deficiency, polydipsia) (470-476).”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [473]

Schizophrenia and smoking: an epidemiological survey in a state hospital
de León, J., Dadvand, M., Canuso, C. M., Odom-White, A., Stanilla, J. K., & Simpson, G. M. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.3.453 · Cited by 417 · see citing works
Decreased Bone Density in Hyperprolactinemic Women
Klibanski, A., Neer, R. M., Beitins, I. Z., Ridgway, E. C., Zervas, N. T., & McArthur, J. W. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032605 · Cited by 358 · see citing works
Polydipsia and water intoxication in psychiatric patients: A review of the epidemiological literature
de León, J., Verghese, C., Tracy, J. I., Josiassen, R. C., & Simpson, G. M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90008-6 · Cited by 279 · see citing works
Self-citation
Osteoporosis in Men with Hyperprolactinemic Hypogonadism
Greenspan, S. L., NEER, R. M., Ridgway, E. C., & KLIBANSKI, A. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-777 · Cited by 249 · see citing works
Clozapine decreases smoking in patients with chronic schizophrenia
McEvoy, J. P., Freudenreich, O., McGee, M., VanderZwaag, C. J., Levin, E. D., & Rose, J. E. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00365-a · Cited by 195 · see citing works
Physical comorbidity and polypharmacy in older psychiatric patients
Larco, J. P., & Jeste, D. V. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91220-3 · Cited by 64 · see citing works
Treatment of Polydipsia and Hyponatremia in Psychiatric Patients
de León, J., Verghese, C., Stanilla, J. K., Lawrence, T., & Simpson, G. M. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00069-c · Cited by 60 · see citing works
Self-citation
Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia
Delva, N. J., Crammer, J., Jarzylo, S., Lawson, J. S., Owen, J. A., Sribney, M., Weir, B., & Yendt, E. R. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90119-4 · Cited by 59 · see citing works
Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine
Kahn, R., Davidson, M., Siever, L. J., Sevy, S. M., & Davis, K. L. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91236-x · Cited by 21 · see citing works

Flagged first, then by citations

Sorted by citations

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Bone Mineral Density in Women with Depression
Michelson, D., Stratakis, C., Hill, L., Reynolds, J., Galliven, E., Chrousos, G., & Gold, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351602 · Cited by 471 · see citing works
Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects
Halbreich, U. M., Kinon, B. J., Gilmore, J. A., & Kahn, L. (2002) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00112-9 · Cited by 250 · see citing works
Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia
Meaney, A. M., Smith, S., Howes, O. D., O'Brien, M., Murray, R. M., & O'Keane, V. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.6.503 · Cited by 217 · see citing works
Neuroleptic-induced hyperprolactinemia
Dickson, R. A. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00159-5 · Cited by 148 · see citing works
Accelerated Osteoporosis in Psychiatric Patients: Possible Pathophysiological Processes
Halbreich, U. M., & Palter, S. F. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.3.447 · Cited by 119 · see citing works
Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents
Naidoo, U., Goff, D. C., & Klibanski, A. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00129-4 · Cited by 113 · see citing works
Bone mass in schizophrenia and normal populations across different decades of life
Renn, J.-H., Yang, N., Chueh, C., Lin, C., Lan, T., & Chou, P. (2009) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-10-1 · Cited by 102 · see citing works
Effects of Elevated Serum Prolactin on Bone Mineral Density and Bone Metabolism in Female Patients With Schizophrenia: A Prospective Study
Abraham, G., Paing, W. W., Kaminski, J., Joseph, A., Kohegyi, E., & Josiassen, R. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1618 · Cited by 82 · see citing works
Self-citation
Cognitive function in euthymic bipolar patients, stabilized schizophrenic patients, and healthy controls
Rossi, A., Arduini, L., Daneluzzo, E., Bustini, M., Prosperini, P., & Stratta, P. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00025-x · Cited by 82 · see citing works
Hyperprolactinemia and Schizophrenia: Mechanisms and Clinical Aspects
Halbreich, U. M., & Kahn, L. S. (2003) · Journal of Psychiatric Practice · doi:10.1097/00131746-200309000-00003 · Cited by 80 · see citing works
The Effects of Atypical Antipsychotics on Serum Prolactin Levels
Hamner, M. B. (2002) · Annals of Clinical Psychiatry · doi:10.1023/a:1021138603935 · Cited by 69 · see citing works
Bone Remodeling, Bone Mass and Weight Gain in Patients with Stabilized Schizophrenia in Real-Life Conditions Treated with Long-Acting Injectable Risperidone
Doknić, M., Marić, N. P., Britvić, D., Pekić, S., Damjanović, A., Miljić, D., Stojanović, M. D. M., Radojicic, Z. A., Gašić, M. J., & POPOVIC, V. M. (2011) · Neuroendocrinology · doi:10.1159/000329391 · Cited by 52 · see citing works
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
Kelly, D. L., Wehring, H. J., Earl, A. K., Sullivan, K. M., Dickerson, F., Feldman, S. M., McMahon, R. P., Buchanan, R. W., Warfel, D. T., Keller, W. R., et al. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-214 · Cited by 45 · see citing works
Osteoporosis, Schizophrenia and Antipsychotics
Halbreich, U. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00003 · Cited by 45 · see citing works
Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
Wu, H., Deng, L., Zhao, L., Zhao, J., Li, L., & Chen, J. (2013) · International Journal of Endocrinology · doi:10.1155/2013/167138 · Cited by 41 · see citing works
High bone turnover but normal bone mineral density in women suffering from schizophrenia
Bergemann, N., Parzer, P., Mundt, C., & Auler, B. (2008) · Psychological Medicine · doi:10.1017/s003329170800319x · Cited by 37 · see citing works
Bone Mineral Density and Osteoporosis Risk in Older Patients With Schizophrenia
Jung, D.-U., Kelly, D. L., Oh, M., Kong, B.-G., Kang, J.-W., Lee, S., & Shim, J.-C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318221b123 · Cited by 34 · see citing works
Osteoporosis Screening and Treatment in Women with Schizophrenia: A Controlled Study
Bishop, J. R., ALEXANDER, B. K., Lund, B. C., & Klepser, T. B. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.5.515.33346 · Cited by 32 · see citing works
Schizophrenia and osteoporosis
Lean, M., & De Smedt, G. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200401000-00006 · Cited by 27 · see citing works
Olanzapine Use in Women With Antipsychotic-Induced Hyperprolactinemia
Canuso, C. M., Hanau, M. S., JHAMB, K. K., & Green, A. I. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1458 · Cited by 28 · see citing works
Children and Adolescents with Severe Mental Illness Need Vitamin D Supplementation Regardless of Disease or Treatment
Bonnot, O., Inaoui, R., Raffin, M., Bodeau, N., Coussieu, C., & Cohen, D. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0079 · Cited by 26 · see citing works
BONE MINERAL DENSITY IN WOMEN WITH DEPRESSION
Ichelson, D. A. M., Ill, L. A. H., Eynolds, J. A. R., Alliven, E. L. G., & Old, P. H. G. (2012) · Cited by 26 · see citing works
No association between bone mass and prolactin levels among patients with schizophrenia
Sugawara, N., Yasui‐Furukori, N., Fujii, A., Saito, M., Sato, Y., Nakagami, T., Tsuchimine, S., & Kaneko, S. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1250 · Cited by 23 · see citing works
Reduced Bone Mineral Density in Patients with Schizophrenia Receiving Prolactin Raising Anti-Psychotic Medication
Meaney, A. M., & O’Keane, V. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103174011 · Cited by 20 · see citing works
Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients
Renn, J.-H., Yang, N.-P., & Chou, P. (2010) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-11-35 · Cited by 17 · see citing works
Osteoporosis demonstrated by dual energy X-ray absorptiometry in chronic schizophrenic patients
Abraham, G., Friedman, R. H., & Verghese, C. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)82517-0 · Cited by 14 · see citing works
Self-citation
Principes de surveillance des effets métaboliques, de l’hyperprolactinémie et du rythme cardiaque pour les antipsychotiques atypiques chez l’enfant et l’adolescent
Bonnot, O., Inaoui, R., Lloret‐Linares, C., & Cohen, D. (2009) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2009.09.004 · Cited by 13 · see citing works
Non‐Neurological Side‐Effects of Antipsychotic Drugs
GOFF, D. C., & Shader, R. I. (2003) · doi:10.1002/9780470987353.ch29 · Cited by 11 · see citing works
Study protocol for the systematic review and meta-analyses of the association between schizophrenia and bone fragility
Manavi, B. A., Stuart, A. L., Pasco, J. A., Hodge, J. M., Corney, K. B., Berk, M., & Williams, L. J. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-041859 · Cited by 5 · see citing works
Şizofrenide Görülen Tıbbi Durumlar
Demirel, B. D., Tamam, L., & Kara, G. K. (2017) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.288680 · Cited by 5 · see citing works
Schizophrenia, Osteoporosis, and an Examination of the Risk of Fractures in Patients Receiving ECT
Andrade, C., Bhakta, S. G., & Singh, N. M. (2007) · Journal of Ect · doi:10.1097/yct.0b013e31814da9c2 · Cited by 3 · see citing works
An audit of the association between the use of antipsychotic medication and bone density measurement in female patients within a special (high security) hospital
Orr, J., & Jamieson, L. (2007) · Journal of Forensic Psychiatry and Psychology · doi:10.1080/14789940701421419 · Cited by 3 · see citing works
Comparison of bone mineral density levels in young-adult patients with schizophrenia and healthy controls / Genç-erişkin şizofreni hastalarında kemik mineral yoğunluğu düzeyinin sağlıklı kontrollerle karşılaştırılması
Koçer, E., Yazıcı, S., & Canan, F. (2011) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn2011240407 · Cited by 3 · see citing works
Prescriptions d'antipsychotiques chez l'enfant et l'adolescent
Bonnot, O., Consoli, A., & Cohen, D. (2011) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(11)53146-3 · Cited by 2 · see citing works
Bone mineral density in patients with depression
Erdal, A., Yıldırım, K., & Karatay, S. (2007) · Journal of Back and Musculoskeletal Rehabilitation · doi:10.3233/bmr-2007-20403 · Cited by 2 · see citing works
Neuropsychiatric Disorders and the Skeleton
Bab, I., & Yirmiya, R. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch120
Antipsikotiklere Bağli Hiperprolaktinemi Antipsychotic-induced Hyperprolactinemia
Bulut, S. (2015)
World Psychiatryis indexed in PubMed, Current Contents/Clinical Medicine, Current Contents/Social and Behavioral Sciences, Science Citation Index, and EMBASE Âñåìèðíàÿ Ïñèõèàòðè÷åñêàÿ Àññîöèàöèÿ (ÂÏÀ)
Maj, M., Ïðåçèäåíò, È., Tasman, A., & Herrman, H. (2011)
Antipsychotic Induced Hyperprolactinemia in Schizophrenia Patients
Bulut, S. D., Bulut, S., & Alataş, E. (2014) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20140509023123

Osteoporosis and Schizophrenia
LEVINE, J., & Belmaker, R. H. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.549-a · Cited by 3 · see citing works
[Osteoporosis risk factors among patients with schizophrenia].
Wyszogrodzka-Kucharska, A., & Rabe‐Jabłońska, J. (2006) · PubMed · Cited by 3 · see citing works
Osteoporosis in patients suffering from schizophrenia
Hummer, M., Malik, P., Gasser, R. W., Kemmler, G., Oehl, M., Hofer, A., Moncayo, F., & Fleischhacker, W. W. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80169-x · Cited by 1 · see citing works
Risk and protective factors across the schizophrenia spectrum
Siever, L. J., Buchsbaum, M. S., Cornblatt, B. A., Harvey, P. D., Bergman, A. J., Siegel, B. V., Hazlett, E., Callahan, A., New, A. S., & Downhill, J. E. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)83958-8
[Risk factors and schizophrenia].
d’Amato, T., & Saoud, M. (1996) · PubMed · Cited by 5 · see citing works

Authors: Abraham, G., Friedman, R. H., Verghese, C., & de Leon, J.
Affiliations: Norristown State Hospital (US)
ORCID: Abraham, George
Verghese, Cherian
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 1995-07
Volume: 38
Issue: 2
Pages: 131-132
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/0006-3223(95)00062-l
OpenAlex: W2048511626
Cited by: 40
References: 9
Citations by year: 2020: 1 · 2017: 1 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 1
FWCI: 1.24
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: osteoporosis, schizophrenia, risk factors, bone health, fracture risk
MeSH terms: Aged, Cross-Sectional Studies, Female, Fractures, Spontaneous, Humans, Male, Osteoporosis, Pennsylvania, Retrospective Studies, Risk Factors, Schizophrenia, Comorbidity, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteoporosis and schizophrenia: Can we limit known risk factors?

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks